BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11472266)

  • 21. Synthesis and biological evaluation of cryptophycin analogs with substitution at C-6 (fragment C region).
    Varie DL; Shih C; Hay DA; Andis SL; Corbett TH; Gossett LS; Janisse SK; Martinelli MJ; Moher ED; Schultz RM; Toth JE
    Bioorg Med Chem Lett; 1999 Feb; 9(3):369-74. PubMed ID: 10091686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid entry into the cryptophycin core via an acyl-beta-lactam macrolactonization: total synthesis of cryptophycin-24.
    Eggen M; Nair SK; Georg GI
    Org Lett; 2001 Jun; 3(12):1813-5. PubMed ID: 11405718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and tissue distribution of cryptophycin 52 (C-52) epoxide and cryptophycin 55 (C-55) chlorohydrin in mice with subcutaneous tumors.
    Boinpally RR; Polin L; Zhou SL; Jasti BR; Wiegand RA; White K; Kushner J; Horwitz JP; Corbett TH; Parchment RE
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):25-33. PubMed ID: 12739061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cryptophycin: a new antimicrotubule agent active against drug-resistant cells.
    Smith CD; Zhang X; Mooberry SL; Patterson GM; Moore RE
    Cancer Res; 1994 Jul; 54(14):3779-84. PubMed ID: 7913408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isolation and structure determination of cryptophycins 38, 326, and 327 from the terrestrial cyanobacterium Nostoc sp. GSV 224.
    Chaganty S; Golakoti T; Heltzel C; Moore RE; Yoshida WY
    J Nat Prod; 2004 Aug; 67(8):1403-6. PubMed ID: 15332864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis of cryptophycin 52 using the sharpless asymmetric dihydroxylation: diol to epoxide transformation optimized for a base-sensitive substrate.
    Liang J; Moher ED; Moore RE; Hoard DW
    J Org Chem; 2000 May; 65(10):3143-7. PubMed ID: 10814209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis of cryptophycins via an N-acyl-beta-lactam macrolactonization.
    Vidya R; Eggen M; Nair SK; Georg GI; Himes RH
    J Org Chem; 2003 Dec; 68(25):9687-93. PubMed ID: 14656095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
    Teicher BA; Chen V; Shih C; Menon K; Forler PA; Phares VG; Amsrud T
    Clin Cancer Res; 2000 Mar; 6(3):1016-23. PubMed ID: 10741729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro effect of cryptophycin 52 on microtubule assembly and tubulin: molecular modeling of the mechanism of action of a new antimitotic drug.
    Barbier P; Gregoire C; Devred F; Sarrazin M; Peyrot V
    Biochemistry; 2001 Nov; 40(45):13510-9. PubMed ID: 11695898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of action of the unusually potent microtubule inhibitor cryptophycin 1.
    Panda D; Himes RH; Moore RE; Wilson L; Jordan MA
    Biochemistry; 1997 Oct; 36(42):12948-53. PubMed ID: 9335554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of macromolecular synthesis by cryptophycin-52.
    Subramanian B; Nakeff A; Media JE; Wiegand RA; Valeriote FA
    Anticancer Drugs; 2002 Nov; 13(10):1061-8. PubMed ID: 12439340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enantioselective synthesis of a 3'-dephenylcryptophycin synthon.
    Eggen MJ; Georg GI
    Bioorg Med Chem Lett; 1998 Nov; 8(22):3177-80. PubMed ID: 9873698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biosynthetic characterization and chemoenzymatic assembly of the cryptophycins. Potent anticancer agents from cyanobionts.
    Magarvey NA; Beck ZQ; Golakoti T; Ding Y; Huber U; Hemscheidt TK; Abelson D; Moore RE; Sherman DH
    ACS Chem Biol; 2006 Dec; 1(12):766-79. PubMed ID: 17240975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis of cryptophycin 52 using the Shi epoxidation.
    Hoard DW; Moher ED; Martinelli MJ; Norman BH
    Org Lett; 2002 May; 4(10):1813-5. PubMed ID: 12000306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient and versatile stereoselective synthesis of cryptophycins.
    Mast CA; Eissler S; Stoncius A; Stammler HG; Neumann B; Sewald N
    Chemistry; 2005 Aug; 11(16):4667-77. PubMed ID: 15915529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and biological evaluation of novel cryptophycin analogs with modification in the beta-alanine region.
    Shih C; Gossett LS; Gruber JM; Grossman CS; Andis SL; Schultz RM; Worzalla JF; Corbett TH; Metz JT
    Bioorg Med Chem Lett; 1999 Jan; 9(1):69-74. PubMed ID: 9990459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "Clicktophycin-52": a bioactive cryptophycin-52 triazole analogue.
    Nahrwold M; Bogner T; Eissler S; Verma S; Sewald N
    Org Lett; 2010 Mar; 12(5):1064-7. PubMed ID: 20131817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cryptophycins as potent payloads for antibody drug conjugates.
    Verma VA; Pillow TH; DePalatis L; Li G; Phillips GL; Polson AG; Raab HE; Spencer S; Zheng B
    Bioorg Med Chem Lett; 2015 Feb; 25(4):864-8. PubMed ID: 25613677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Versatile Chemoenzymatic Synthesis for the Discovery of Potent Cryptophycin Analogs.
    Schmidt JJ; Khatri Y; Brody SI; Zhu C; Pietraszkiewicz H; Valeriote FA; Sherman DH
    ACS Chem Biol; 2020 Feb; 15(2):524-532. PubMed ID: 31961651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Jasplakinolide: interaction with radiation and hyperthermia in human prostate carcinoma and Lewis lung carcinoma.
    Takeuchi H; Ara G; Sausville EA; Teicher B
    Cancer Chemother Pharmacol; 1998; 42(6):491-6. PubMed ID: 9788576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.